在癌症治疗期间使用-葡萄糖共载体2抑制剂:益处,风险和正在进行的临床试验
Nichanan Osataphan1,2, Husam Abdel-Qadir1,3, Agnieszka Maria Zebrowska4,5
1Division of Cardiology, Ted Rogers Program in Cardiotoxicity Prevention, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.
-葡萄糖携带载体-2 抑制剂 (SGLT-2i) 显示出在预防反环素诱导的心脏毒性方面具有前景. 需要进一步的随机对照试验来确认它们在癌症患者中的心脏保护作用.
科学领域:
- 心脏病学 心脏病学
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 人环素是重要的化疗剂,但可以引起心脏毒性.
- 预防化疗诱导的心脏毒性对于癌症患者的治疗结果至关重要.
- -葡萄糖共传输体-2 抑制剂 (SGLT-2i) 已被批准用于糖尿病和心力衰竭.
研究的目的:
- 审查目前关于SGLT-2i用于预防反环素诱导心脏毒性的数据.
- 探索SGLT-2i心脏保护的潜在机制和新出现的证据.
主要方法:
- 现有研究和正在进行的研究的文献综述.
- 对SGLT-2i对心脏作用的拟议机制的分析.
主要成果:
- 通过各种途径,SGLT-2i可能会提供对环素心脏毒性的保护.
- 来自基础科学和观测研究的新兴证据支持这种潜力.
- 建议的机制包括代谢,血液动力学和抗炎作用.
结论:
- 在接受 antracyclines 的患者中,SGLT-2i 显示出作为心脏保护策略的潜力.
- 进一步的随机对照试验对于确定有效性和安全性至关重要.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
07:29Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
相关概念视频
Secondary Active Transport
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Glucose Absorption Into the Small Intestine
Oral Hypoglycemic Agents: Glinides
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)